-
Mashup Score: 32Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study - 20 day(s) ago
Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced proteinuria and attenuated AP activation in a Phase 2 study of patients with IgAN, thereby supporting the rationale for its evaluation in a Phase 3 study.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 35
In their recent study Maritati and colleagues reported 45 patients with early onset TMA after kidney transplantation.[1] Using serum of these patients an increased C5b-9 deposition on endothelial cells was observed in 84%. The authors suggest that these positive test results support the effective use of eculizumab. We caution against such conclusion. Initially, it was hoped that the ex-vivo complement assay would allow to evaluate the presence of factors in serum that augment complement activation on endothelial cells, and to identify patients with (risk of) TMA caused by complement dysregulation.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 6Effect of Belimumab on Preventing de novo Renal Lupus Flares - 3 month(s) ago
Belimumab was recently approved for treating lupus nephritis (LN), yet de novo LN cases during belimumab treatment given for nonrenal causes have been reported. Identification of reliable signals of impending flare is imperative.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 10Updates on New Therapies for Patients with CKD - 3 month(s) ago
Individuals diagnosed with chronic kidney disease (CKD) continue to increase globally. This group of patients experience a disproportionately higher risk of cardiovascular (CV) events compared to the general population. Despite multiple guidelines-based medical management, patients with CKD continue to experience residual cardiorenal risk. Several potential mechanisms explain this excessive CV risk observed in individuals with CKD. Several new drugs have become available that could potentially transform CKD care, given their efficacy in this patient population.
Source: www.kireports.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 7
While the numbers of women pursuing a career in nephrology have been increasing worldwide, there remain barriers to career achievement. Today, thanks to women pioneers such as Drs Renee Habib, Marie-Claire Gubler, Sharon Anderson, Priscilla Kincaid-Smith, Saraladevi Naicker and many others, gender is not a barrier to complete medical studies and elect nephrology as a specialty. In 2009 women represented just 33% of the nephrologists practicing in France, fourteen years later this number is around 48%.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 1Current Issue Table of Contents: Kidney International Reports - 5 month(s) ago
Society Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 55The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice dataset - 5 month(s) ago
The prevalence of chronic kidney disease (CKD) in Australia varies substantially across reports. Using a large, nationally representative general practice data source, we determined the contemporary prevalence and staging of CKD in Australian primary care.
Source: www.kireports.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis - 5 month(s) ago
Focal segmental glomerulosclerosis (FSGS), a histologic lesion in the kidney caused by varied pathophysiological processes, leads to end-stage kidney disease in a large proportion of patients. Sparsentan is a first-in-class orally active compound combining endothelin type A (ETA) receptor blockade with angiotensin II type 1 (AT1) receptor antagonism in a single molecule. A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS (DUPLEX) study evaluates the long-term antiproteinuric efficacy, nephroprotective potential, and safety profile of sparsentan compared with an AT1 receptor blocker alone in patients with FSGS.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 52Implementation of a one-day living kidney donor evaluation program: A qualitative analysis of donor candidate and stakeholder perspectives - 6 month(s) ago
A lengthy donor evaluation process hinders living kidney donor transplantation (LDKT). At The Ottawa Hospital, one-day evaluation process was recently developed, with a goal to accelerate the determination of donor suitability. The major objective of this study was to solicit feedback from donor candidates and key stakeholders who participated in the one-day living kidney donor evaluation process, to determine the program’s acceptability and factors influencing its implementation elsewhere.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 2Patient Survival With Extended Home Hemodialysis Compared to In-center Conventional Hemodialysis - 7 month(s) ago
More frequent and/or longer hemodialysis (HD) has been associated with improvements in numerous clinical outcomes in patients on dialysis. Home HD (HHD), which allows more frequent and/or longer dialysis with lower cost and flexibility in treatment planning, is not widely used worldwide. Although, retrospective studies have indicated better survival with HHD, this issue remains controversial. In this multicenter study, we compared thrice-weekly extended HHD with in-center conventional HD (ICHD) in a large patient population with a long-term follow-up.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
Next up is Dana Rizk from @UAB_NRTC Starts ‘IgA Nephropathy is most common ……’ of course On Iptacopan in IgA Their protocol here https://t.co/AtNquIEA6O #ISNWCN